A revival in AstraZeneca Plc shares faces a key test this week, with more likely to hinge on the drugmaker’s ability to ...

AstraZeneca scrapped plans for a £450 million UK vaccine plant after rejecting a £78 million government offer, citing ...

AstraZeneca share rose after it that the company has secured permission to import pharmaceutical formulations of new drug for sale or for distribution in Form CT-20 from CDSCO ...

If you purchased or acquired securities in AstraZeneca between between February 23, 2022 and December 17, 2024 and would like ...

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Astrazeneca (AZN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the ...

Britain on Monday hit back at AstraZeneca over the collapse of a 450 million pound ($558.5 million) investment, saying the drugmaker had scaled back the research and development portion of its plans, ...

Mediolanum International Funds Ltd decreased its holdings in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 67.7% ...

AstraZeneca is a leader in cancer treatments with FDA-approved drugs. Read why AZN stock is still a 'Buy' and why the company’s future looks bright.

AstraZeneca on Friday scrapped plans to invest 450 million pounds ($558.3 million) in its vaccine manufacturing plant in ...

Investment analysts at Leerink Partnrs upped their FY2026 EPS estimates for shares of AstraZeneca in a note issued to ...

(Alliance News) - AstraZeneca PLC on Monday said Imfinzi has been recommended for approval in the EU as monotherapy for limited-stage small cell lung cancer.

AstraZeneca Plc abandoned plans to invest £450 million ($558 million) in a UK vaccine manufacturing plant, following protracted wrangling with the new Labour government over the level of state funding ...